David Peritt

Company: Lupagen

Job title: Founder & Chief Scientific Officer

Seminars:

Panel Discussion: Opportunities & Challenges to Optimize In Vivo RNA Engineering 10:30 am

Elucidating the opportunities for in vivo cell therapy to minimize current ex vivo bottlenecks and the role of RNA engineering in producing versatile therapies Achieving a transient vs. longer term effect for different indications with RNA modification Maintaining consistent in vivo production of RNA to yield long-term responsesRead more

day: Day Two